Stemware... All About StemCell Stocks

[JamaicaBaby]

Aastrom gets OK for late-stage trial of bone-death treatment
Mon May 7, 2007 6:43pm ET
Market View
ASTM (Aastrom Biosciences Inc )
Last: $1.44
Change: +0.03 (+2.13%)
Revenue (ttm): M
EPS:
Market Cap: M
Time: 3:59pm ET



Stock Details
Company Profile
Analyst Research
Company News:
Aastrom gets OK for late-stage trial of bone-death treatment
Aastrom reports Q2 results
More Company News... Email This Article | Print This Article | Reprints [-] Text [+]
May 7 (Reuters) - Aastrom Biosciences Inc. (ASTM.O: Quote, Profile , Research) said the U.S. health regulators approved the company's investigational new drug application to initiate a late-stage trial for the treatment of bone death due to lack of blood supply.

The treatment is for osteonecrosis of the femoral head, Aastrom Biosciences said in a statement. (Reporting by Anup Roy in Bangalore)


Reuters Pictures

Editors Choice: Best pictures
from the last 24 hours.
View Slideshow

© Reuters 2007. All Rights Reserved.